Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07591649 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

Name: Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT — clinical trial record (NCT07591649)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1/2

SponsorMasonic Cancer Center, University of Minnesota

Started2026-05-08

View on ClinicalTrials.gov ↗

Amendment history

2026-05-15

Study Status, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-06-01→confirmed 2026-05-08

2026-05-11

Original filing

Masonic Cancer Center, University of Minnesota

58 trials monitored

See 2 trials at risk

Leukemia

2,553 trials monitored

See 134 trials at risk

Acute Myeloid Leukemia (AML)

1,196 trials monitored

See 63 trials at risk

This is a multi-institutional Phase I/II study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy \[cyclophosphamide (CY)/fludarabine (FLU)\] in patients with relapsed or refractory acute myelogenous leukemia (AML). AdaptNK is a natural killer (NK) cell product that is enriched for NK cells with an "adaptive", or human cytomegalovirus (CMV)-induced, phenotype.

Trial Details

NCT Number	NCT07591649
Lead Sponsor	Masonic Cancer Center, University of Minnesota
Conditions	Relapsed Adult AML, Refractory AML, Acute Myelogenous Leukemia
Enrollment	18 participants
Start Date	2026-05-08
Primary Completion	2030-03-01 (estimated)
Study Completion	2035-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-19